Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.